BioSpace News Archive

Drug Development

Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

Investigational oral BTK inhibitor demonstrates rapid onset and increased treatment responses over time as well as a favorable tolerability profile in 31 patients who have no other treatment options

December 7, 2019
·
6 min read
Biotech Beach

Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

Study results showed EPIDIOLEX significantly reduced difficult-to-treat seizures associated with TSC and improved overall patient condition as reported by caregivers

December 7, 2019
·
8 min read
Drug Development

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment

47 Percent of Refractory Large B-cell Lymphoma Patients in ZUMA-1 Pivotal Phase 2 Cohorts Were Alive Three Years after a Single Infusion of Yescarta

December 7, 2019
·
12 min read
Pharm Country

Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study

Data from the pivotal liso-cel TRANSCEND NHL 001 study demonstrate patients with relapsed/refractory large B-cell lymphomas experienced high rate of durable responses

December 7, 2019
·
9 min read
Genetown

Aleta Biotherapeutics Presents In Vivo Results of a Novel Therapeutic Designed to Reactivate CAR T Cells in Patients Who Relapse After CAR T Therapy

Novel CD19-anti-CD20 bridging protein technology to prevent and reverse relapse presented at ASH 2019

December 7, 2019
·
3 min read
Genetown

Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting

Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL

December 7, 2019
·
7 min read
Genetown

First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers

Magenta Therapeutics announced that new results from its MGTA-145 stem cell mobilization program were presented at the 61st Annual Meeting of the American Society of Hematology.

December 7, 2019
·
7 min read
Policy

Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome

December 7, 2019
·
10 min read
BioForest

Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting

Additional Analysis in Phase 2 Trial of ADCETRIS plus OPDIVO in Patients with Frontline Hodgkin Lymphoma Aged 60 Years and Older

December 7, 2019
·
16 min read
Policy

BAXTER LOSS ALERT: ROSEN LAW FIRM Reminds Baxter International Inc. Investors of Important January 24th Deadline in Securities Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Baxter International Inc. between February 21, 2019 and October 23, 2019, inclusive of the important January 24, 2020 lead plaintiff deadline in the case.

December 7, 2019
·
3 min read